Heart Health Is Brain Health, and It Starts in Your 20s
New research pushes back the age at which dementia risk from cardiovascular and metabolic factors begins. Should protective lifestyle interventions start in youth?
ALL NEWS
208 RESULTS
Sort By:
- Most Recent
- Most Commented
Alzheimer's Association International Conference 2020 (Virtual Meeting Only)
Plasma p-Tau217 Set to Transform Alzheimer’s Diagnostics Could Common Vaccines Protect Against Alzheimer’s Disease? Doubling Down on Sequencing Serves up More Alzheimer’s Genes IDEAS Finds Small Drop in Hospitalizations, Missing Goal Lancet Commission’s ...
Confused About the DIAN-TU Trial Data? Experts Discuss
The AAT-AD/PD conference hosted a virtual conversation about what the trial’s disappointing cognitive and tantalizing biomarker data might mean. Hidden between thank you’s and pledges to stay committed were substantive points of debate and context.
Umibecestat-Driven Cognitive Decline Is Reversible
Subtle memory deficits resolved after volunteers stopped taking the Novartis BACE inhibitor.
At AAIC, Hints of Target Engagement for Some Drug Candidates
Early data suggest that CT1812 and AL001 shift biomarker levels in Alzheimer’s disease and frontotemporal dementia, respectively. BI 425809 fails to improve cognition.
FDA Accepts Aducanumab Application for Priority Review
The FDA will decide whether to approve the antibody as a treatment for Alzheimer’s disease on or before March 7, 2021.
Global Genetics Symposium Starts Today
Three weeks of on-demand seminars to culminate in live Q&A.
Mutation in the Parkinson’s Gene DJ-1 Derails Splicing
Restoring proper gene editing assuaged mitochondrial defects in patient-derived neurons and organoids. Splicing errors may underlie other PD cases as well.
New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better
At AAT-ADPD, researchers report how they built on prior reports that a person’s blood level of p-tau181 tells if they have Alzheimer’s.
In APP Knock-In Mice, Spatial Mapping Circuitry Crumbles
Poor coordination among grid cells in the entorhinal cortex and place cells in the hippocampus compromises navigation. Grid cells fail first.
Biogen Asks FDA To Approve Aducanumab
New drug application is first for Alzheimer’s disease in the U.S. since 2003, and first based on amyloid hypothesis.
Seeing into the Human Synapse: New Tools Illuminate Alzheimer’s Hot Spot
New synaptic profiling and imaging techniques are enabling scientists to zero in on synaptic proteins, including phospho-tau, that make the difference between clinical Alzheimer’s and resilience.
Amyloid Clearance: Check. Cognitive Benefit: Um … Maybe.
Plaque-busting antibodies reset the time course of amyloid accumulation, but so far provide only hints of a clinical benefit in mild AD. Good news: once gone, plaque stays gone for a while.
Current Filters
- Date Range : Sep 2019 to Sep 2020 x